Sun Pharmaceutical Industries Limited (SUNPHARMA.BO)

1,517.90 +0.75 (+0.05%) 市場開市。 截至 02:53PM IST。

Sun Pharmaceutical Industries Limited

Sun House
Plot No. 201 B/1 Western Express Highway Goregaon (East)
Mumbai 400063
India
91 22 4324 4324
https://www.sunpharma.com

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 41,000

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Dilip Shantilal Shanghvi	MD & Executive Director	54.53M	無	1955
Mr. Kalyanasundaram Subramanian	Director of Corporate Development	65.3M	無	1954
Mr. C. S. Muralidharan	Chief Financial Officer	38.89M	無	1963
Mr. Davinder Singh	Executive Vice-President of Global Operations	無	無	無
Mr. Dheeraj Prasad Sinha BE	EVP & Chief Information Officer	無	無	1971
Mr. Nimish Desai	Head of Investor Relations	無	無	無
Mr. Anoop Deshpande	Company Secretary & Compliance Officer	無	無	無
Mr. Suresh Kumar Rai	Chief Human Resources Officer	無	無	無
Mr. Kirti Wardhaman Ganorkar	Chief Executive Officer of India Business	無	無	1967
Mr. Aalok Dilip Shanghvi	Executive VP, Head of Emerging Markets, Global Generics R&D, Business Devp., and Whole Time Director	無	無	1984

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 INR。

描述

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It provides APIs for anti-cancers, peptides, steroids, hormones, and immunosuppressant drugs. In addition, the company offers generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, and anti retro viral medications, as well as over-the-counter products. The company was founded in 1983 and is based in Mumbai, India.

公司管治

截至 2024年4月1日 止，Sun Pharmaceutical Industries Limited 的 ISS 管治質素評分為 2。 Pillar 分數正在審核中：4；董事會：2；股東權利：1；現金賠償：6。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。